Alkermes (NASDAQ:ALKS) Stock Price Down 5.6% – Here’s What Happened

Posted by Brian Himes on Sep 18th, 2026

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) traded down 5.6% during trading on Friday . The company traded as low as $44.20 and last traded at $44.10. Approximately 903,780 shares were traded during mid-day trading, a decline of 57% from the average session volume of 2,092,249 shares. The stock had previously closed at $46.71.

Analyst Upgrades and Downgrades

ALKS has been the subject of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $65.00 price target (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. Stifel Nicolaus restated a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. Bank of America reaffirmed an “underperform” rating on shares of Alkermes in a report on Monday, June 29th. TD Cowen lifted their price target on Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Finally, Wells Fargo & Company raised their price objective on shares of Alkermes from $44.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 29th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $54.56.

View Our Latest Stock Analysis on ALKS

Alkermes Trading Down 5.5%

The stock has a market capitalization of $7.40 billion, a P/E ratio of 116.11 and a beta of 0.31. The company has a current ratio of 2.30, a quick ratio of 1.85 and a debt-to-equity ratio of 0.82. The stock’s fifty day moving average price is $49.15 and its two-hundred day moving average price is $41.84.

Insider Buying and Selling at Alkermes

In other Alkermes news, Director Nancy Lynn Md Snyderman sold 44,472 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $50.35, for a total transaction of $2,239,165.20. Following the completion of the sale, the director directly owned 15,395 shares in the company, valued at $775,138.25. This represents a 74.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total value of $422,910.00. Following the completion of the transaction, the executive vice president owned 65,389 shares in the company, valued at approximately $3,072,629.11. This represents a 12.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 85,150 shares of company stock valued at $4,242,213. Company insiders own 4.59% of the company’s stock.

Institutional Trading of Alkermes

Several hedge funds and other institutional investors have recently bought and sold shares of ALKS. Cullen Frost Bankers Inc. purchased a new stake in shares of Alkermes in the fourth quarter worth $28,000. Ameritas Advisory Services LLC purchased a new position in shares of Alkermes in the 2nd quarter worth about $39,000. Hantz Financial Services Inc. boosted its stake in Alkermes by 65.1% in the 4th quarter. Hantz Financial Services Inc. now owns 2,045 shares of the company’s stock worth $57,000 after purchasing an additional 806 shares in the last quarter. Leonteq Securities AG bought a new position in Alkermes in the 4th quarter worth about $70,000. Finally, Versant Capital Management Inc grew its position in Alkermes by 33.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after purchasing an additional 366 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

(Get Free Report)

Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities include treatments for schizophrenia, bipolar disorder, addiction and other serious neurological or psychiatric conditions, with an emphasis on long-acting injectable and extended-release formulations.

The company’s marketed products include VIVITROL, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence after detoxification; ARISTADA, an extended-release injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults; and LYBALVI, an oral combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in Ireland in 1987, Alkermes has developed drug-delivery technologies intended to help extend dosing intervals and support medication adherence.